Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), demonstrating best-in-class efficacy potential and a safety profile consistent with in-class comparators

Announced enrollment completion for the Phase 2 SKYWAY basket trial (“SKYWAY”), with all three sub-studies over-enrolling on or ahead of schedule, which we believe reflects significant investigator enthusiasm for new treatment options in these indications